Baillie Gifford & CO Seagen Inc. Transaction History

Baillie Gifford & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 02, 2021	SELL	$135.08 - $161.1 $2,566 - $3,060	-19 Reduced 12.93%	128 $20,000
Q1 2021 May 06, 2021	SELL	$137.51 - $190.8 $446 Million - $619 Million	-3,243,632 Reduced 100.0%	147 $20,000
Q4 2020 Feb 10, 2021	SELL	$164.63 - $211.93 $8.42 Million - $10.8 Million	-51,130 Reduced 1.55%	3,243,779 $568 Million
Q3 2020 Nov 12, 2020	BUY	$145.95 - $195.69 $481 Million - $645 Million	3,294,909 New	3,294,909 $645 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.